Scotiabank lowered the firm’s price target on Myriad Genetics (MYGN) to $24 from $34 and keeps an Outperform rating on the shares. The firm lowered its estimates for 2025 to reflect the recent medical policy change by UnitedHealth (UNH) to no longer cover PGx panel testing, the analyst tells investors. Scotiabank, however, continues to see significant upside potential if the company continues to deliver on double-digit top line growth, profitability targets, and pipeline progress.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics expands access to at-home early fetal sex DNA test
- Myriad Genetics price target lowered to $24 from $30 at Piper Sandler
- Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges
- Myriad Genetics price target lowered to $20 from $30 at TD Cowen
- Myriad Genetics reports Q3 adjusted EPS 6c, consensus 2c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
